BR112013020643A2 - métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato - Google Patents

métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato

Info

Publication number
BR112013020643A2
BR112013020643A2 BR112013020643A BR112013020643A BR112013020643A2 BR 112013020643 A2 BR112013020643 A2 BR 112013020643A2 BR 112013020643 A BR112013020643 A BR 112013020643A BR 112013020643 A BR112013020643 A BR 112013020643A BR 112013020643 A2 BR112013020643 A2 BR 112013020643A2
Authority
BR
Brazil
Prior art keywords
beta
methylbutyrate
hydroxy
methods
cognitive function
Prior art date
Application number
BR112013020643A
Other languages
English (en)
Portuguese (pt)
Inventor
Alejandro Barranco Perez Gonzales
Jose Maria Lopez Pedrosa
Manuel Manzano Martin
Maria Ramirez Gonzalez
Ricardo Rueda Canbrera
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR112013020643A2 publication Critical patent/BR112013020643A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112013020643A 2011-02-17 2012-02-13 métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato BR112013020643A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443762P 2011-02-17 2011-02-17
PCT/US2012/024817 WO2012112419A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Publications (1)

Publication Number Publication Date
BR112013020643A2 true BR112013020643A2 (pt) 2016-08-02

Family

ID=45757211

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020643A BR112013020643A2 (pt) 2011-02-17 2012-02-13 métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato

Country Status (12)

Country Link
US (1) US9326956B2 (https=)
EP (1) EP2675298A1 (https=)
JP (2) JP6034309B2 (https=)
CN (1) CN103347406B (https=)
AR (1) AR085297A1 (https=)
BR (1) BR112013020643A2 (https=)
CA (1) CA2825734C (https=)
MX (1) MX348708B (https=)
PH (1) PH12013501671A1 (https=)
SG (1) SG192813A1 (https=)
TW (1) TWI565420B (https=)
WO (1) WO2012112419A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
JP5892948B2 (ja) 2010-01-29 2016-03-23 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ カルシウムｈｍｂを含む栄養エマルジョン
BR112012018174A2 (pt) 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CN103347406B (zh) 2011-02-17 2015-08-05 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
EP2745708A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
WO2014120730A2 (en) * 2013-01-29 2014-08-07 Otc Nutrition Llc Micronutrient fortification delivery
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
MX2015013179A (es) * 2013-03-15 2016-04-20 Abbott Lab Formula infantil con bajo contenido calorico que contiene acido beta-hidroxi-beta-metilbutirico.
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
ES2806684T3 (es) * 2015-09-16 2021-02-18 Abbott Lab Composición nutricional líquida, de larga duración y reducida en grasas
CN108770334B (zh) * 2015-11-10 2022-10-28 代谢科技有限公司 β-羟基-β-甲基丁酸系化合物(HMB)的组合物和使用其作为动物饲料添加剂的方法
JP7011300B2 (ja) * 2017-12-19 2022-02-10 株式会社島田製薬 ＨＭＢＣａ含有顆粒の製造方法、及びサプリメント

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291525B1 (en) * 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
PL371081A1 (pl) 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
WO2007056176A2 (en) 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
CA2746420C (en) 2008-12-09 2019-11-12 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP2009155336A (ja) 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
TW201117736A (en) 2009-11-17 2011-06-01 Hui-Chiang Lu Compositions for sport supplement
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
SG191315A1 (en) 2010-12-22 2013-07-31 Abbott Lab Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid
CA2821312A1 (en) 2010-12-27 2012-07-05 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
CN103347406B (zh) 2011-02-17 2015-08-05 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法
CN104411305A (zh) 2012-03-19 2015-03-11 雅培制药有限公司 用于改善葡萄糖耐受的β-羟基-β-甲基丁酸
CA2885211A1 (en) 2012-09-17 2014-03-20 Abbott Laboratories Beta-hydroxy-beta-methylbutyric acid-containing compositions and uses thereof

Also Published As

Publication number Publication date
CN103347406A (zh) 2013-10-09
JP2014506890A (ja) 2014-03-20
TW201309212A (zh) 2013-03-01
US20140249223A1 (en) 2014-09-04
WO2012112419A1 (en) 2012-08-23
MX348708B (es) 2017-06-26
SG192813A1 (en) 2013-09-30
JP2017061483A (ja) 2017-03-30
EP2675298A1 (en) 2013-12-25
WO2012112419A8 (en) 2014-03-06
US9326956B2 (en) 2016-05-03
CA2825734C (en) 2016-05-17
TWI565420B (zh) 2017-01-11
JP6340394B2 (ja) 2018-06-06
PH12013501671A1 (en) 2021-06-02
JP6034309B2 (ja) 2016-11-30
MX2013009528A (es) 2013-10-01
AR085297A1 (es) 2013-09-18
CN103347406B (zh) 2015-08-05
CA2825734A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
BR112013020643A2 (pt) métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato
BR112013031209A2 (pt) método para produção de hidrógéis
BR302013001048S1 (pt) Configuração aplicada em componente para lentes
BR112015003453A2 (pt) redes de fixação mecânica e métodos para a produção das mesmas
BR112013020220A2 (pt) métodos para determinação de ploidia pré-natal não invasiva
ZA201304334B (en) Methods for diagnosing and treating eye-length related disorders
ITMI20121896A1 (it) Mems-chippackage e procedimento per fabbricare un mems-chippackage
DE102012217865A8 (de) Luftreifen
IL230654A0 (en) Methods and apparatus for improving management of nfc logical connections
BR112013019076A2 (pt) conjunto de peneira e um método para a respectiva construção
IL235780A0 (en) Pul-core method with a pmi foam core
PT2877587T (pt) Método para a produção de metano e aparelho adequado para o efeito
CO7081159A2 (es) Métodos para producir compuestos sulfilimina
BR112014023854A2 (pt) Método para montar um distalizador e distalizador
EP2795554A4 (en) LIFE ADVISOR APPLICATION FOR PERFORMING TASKS
CO6842021A2 (es) Análogos de ácido epoxieicosatrienoico y métodos para elaborarlosy utilizarlos
BR112014009601A2 (pt) processo para a preparação de granulados de poliamida e utilização do processo
IL238188B (en) Method for quantifying brain injuries
BR112013024413A2 (pt) compostos e métodos para a preparação de diarilpropanos
PT2718434T (pt) Composições e métodos para tratar a doença de espru celíaco
BRDI7105327S (pt) Configuração aplicada em estojo para peças de dominó
BR112015000987A2 (pt) processo para a preparação de 5-fluoro-1h-pirazóis
BR112013023130A2 (pt) processo de redução assimétrica
PL2705353T3 (pl) Sposób i zespół do badania zgodności z minimalnym współczynnikiem odblasku
BR112014014577A2 (pt) processo autotérmico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/19 (2006.01), A23L 33/10 (2016.01), A23L 3

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2449 DE 12-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.